Abstract Purpose of Review Thiazolidinediones (TZDs) are the only pharmacologic agents
that specifically treat insulin resistance. The beneficial effects of TZDs on the cardiovascular …

Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular
complications, which represent the major cause of mortality. Despite effective treatment of …

Thiazolidinediones (TZDs) are potent insulin sensitizers that act through the nuclear
receptor peroxisome proliferator-activated receptor-γ (PPARγ) and are highly effective oral …

Peroxisome proliferator–activated receptors (PPARs) regulate energy metabolism and
hence are therapeutic targets in metabolic diseases such as type 2 diabetes and non …

Type 2 diabetes is caused by insulin resistance coupled with an inability to produce enough
insulin to control blood glucose, and thiazolidinediones (TZDs) are the only current …

The PPARs are a subfamily of three ligand-inducible transcription factors, which belong to
the superfamily of nuclear hormone receptors. In mammals, the PPAR subfamily consists of …

Insulin resistance is a hallmark of type 2 diabetes mellitus and is associated with a metabolic
and cardiovascular cluster of disorders (dyslipidaemia, hypertension, obesity [especially …

Overnutrition and sedentary activity reinforce the growing trend of worldwide obesity, insulin
resistance, and type 2 diabetes. However, we have limited insight into how food intake …

Being overweight or obese is a worldwide epidemic. Adiposity can cause fat mass–related
cardiovascular disease (CVD). Adiposity may also cause adipocyte and adipose tissue …

BACKGROUND A growing body of evidence from epidemiological data, animal studies, and
clinical trials supports HDL as the next target to reduce residual cardiovascular risk in statin …